Evidence map›Paper›PMID 1863023›Full record

ArticleAnnals of internal medicine1991

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

G E D'Alonzo, R J Barst, S M Ayres, E H Bergofsky, B H Brundage, K M Detre, A P Fishman, R M Goldring, B M Groves, J T Kernis

7 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Annals of internal medicine, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 1,082 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,082citing papers in PubMed, 3 pooled it
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03617458 phase2completedstarted 2018, after this paper: background citation

Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension

Ran2018Enrolled73Registered outcomes39Posted comparisons0ConditionsPulmonary Artery HypertensionArmsMetformin, mHealth Intervention, Placebo, Usual Care
PMID 22723290PMID 22281797other papers from this trial
Open the trial in the graph
NCT00098072 phase1completednot on this mapstarted 2000, after this paper: background citation

Endothelial Cell Dysfunction in Pulmonary Arterial Hypertension: Biomarkers, Mechanisms of Disease and Novel Therapeutic Targets

TypeinterventionalSponsorNational Institutes of Health Clinical Center (CC)Ran2000 to 2009Enrolled27ConditionsSecondary Pulmonary Arterial HypertensionArmsHeart Catheterization
NCT01417338 unknown statusnot on this mapstarted 2009, after this paper: background citation

National, Prospective, Multicenter,Observational Registry Study on Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension in China

TypeobservationalSponsorChinese Academy of Medical Sciences, Fuwai HospitalRan2009 to 2020Enrolled3,079ConditionsPulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Death
NCT01730092 recruitingnot on this mapstarted 2013, after this paper: background citation

A Natural History Study of Novel Biomarkers in Pulmonary Arterial Hypertension

TypeobservationalSponsorNational Institutes of Health Clinical Center (CC)Ran2013Enrolled270ConditionsPulmonary Disease, Pulmonary Hypertension
NCT02729844 completednot on this mapstarted 2016, after this paper: background citation

Pulmonary Hypertension in Preterm Children Born at Gestational Age <30 Weeks: Prevalence, Risk Factors and Outcome

Typeobservational_patient_registrySponsorUniversity Medical Center GroningenRan2016 to 2021Enrolled134ConditionsPulmonary Hypertension, Bronchopulmonary Dysplasia
NCT03935178 terminatednot on this mapstarted 2019, after this paper: background citation

A Single-Center, Blinded, Randomized Control Trial Evaluating Different Approaches to Evaluation of Right Ventricular Size and Function Using the Upper Valley Right Ventricle Algorithm and Novel Imaging Modalities

TypeobservationalSponsorDartmouth-Hitchcock Medical CenterRan2019 to 2022Enrolled14ConditionsPulmonary Hypertension, Valvular Heart Disease, Congenital Heart Disease, Congestive Heart FailureArmsMeasuring Right Ventricular Size and Function
NCT05618093 nawithdrawnnot on this mapstarted 2023, after this paper: background citation

Use of Non-invasive Measurement of Cardiac Output and Stroke Volume to Assess Risk and Response to Treatment in Patients With PAH or CTEPH

TypeinterventionalSponsorUniversity of California, Los AngelesRan2023 to 2024Enrolled0ConditionsPulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary HypertensionArmsNon-invasive hemodynamic measurements
3 · Its place in the literature

Who cites it

1,082 citing papers in PubMed, 3 syntheses or guidelines pooled it, 3,486 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

1,022 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 12 institutions in 1 country.

G E D'AlonzoDivision of Lung Diseases, National Heart, Lung, and Blood Institute, Bethesda, MD 20892.
R J Barst
S M Ayres
E H Bergofsky
B H Brundage
K M Detre
A P Fishman
R M Goldring
B M Groves
J T Kernis
University of Illinois Chicago · USNational Institutes of Health · USUniversity of Colorado Denver · USCleveland Clinic · USHarvard University Press · USLittle Company of Mary Hospital · USNew York University · USStony Brook University · USThe University of Texas Health Science Center at Houston · USUniversity of California, Los Angeles · USUniversity of Pittsburgh · USVirginia Commonwealth University · US

Funding

REGISTRY TO CHARACTERIZE PRIMARY PULMONARY HYPERTENSIONN01HR014000 · HR · UNIVERSITY OF ILLINOIS AT CHICAGO · PI LEVY, PAUL S · 1985 to 1988
–
NHLBI NIH HHS N01-HR-14000
6 · The paper itself

Abstract

objectiveTo characterize mortality in persons diagnosed with primary pulmonary hypertension and to investigate factors associated with survival.

designRegistry with prospective follow-up.

settingThirty-two clinical centers in the United States participating in the Patient Registry for the Characterization of Primary Pulmonary Hypertension supported by the National Heart, Lung, and Blood Institute. PATIENTS: Patients (194) diagnosed at clinical centers between 1 July 1981 and 31 December 1985 and followed through 8 August 1988. MEASUREMENTS: At diagnosis, measurements of hemodynamic variables, pulmonary function, and gas exchange variables were taken in addition to information on demographic variables, medical history, and life-style. Patients were followed for survival at 6-month intervals. MAIN

resultsThe estimated median survival of these patients was 2.8 years (95% Cl, 1.9 to 3.7 years). Estimated single-year survival rates were as follows: at 1 year, 68% (Cl, 61% to 75%); at 3 years, 48% (Cl, 41% to 55%); and at 5 years, 34% (Cl, 24% to 44%). Variables associated with poor survival included a New York Heart Association (NYHA) functional class of III or IV, presence of Raynaud phenomenon, elevated mean right atrial pressure, elevated mean pulmonary artery pressure, decreased cardiac index, and decreased diffusing capacity for carbon monoxide (DLCO). Drug therapy at entry or discharge was not associated with survival duration.

conclusionsMortality was most closely associated with right ventricular hemodynamic function and can be characterized by means of an equation using three variables: mean pulmonary artery pressure, mean right atrial pressure, and cardiac index. Such an equation, once validated prospectively, could be used as an adjunct in planning treatment strategies and allocating medical resources.

Indexed as

AdultAnalysis of VarianceFemaleFollow-Up StudiesHemodynamicsHumansHypertension, PulmonaryLife TablesMaleMiddle AgedMultivariate AnalysisOdds RatioProspective StudiesRegistriesRespiratory Function TestsSurvival Rate

Identifiers

PMID1863023
OpenAlexW2141987653

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

and 1 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.